Surmodics (SRDX) 10-Q 28 Apr 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Mar. 31, 2021	Apr. 23, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	SRDX
Security Exchange Name	NASDAQ
Entity Registrant Name	Surmodics, Inc.
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, $0.05 par value
Entity File Number	0-23837
Entity Incorporation, State or Country Code	MN
Entity Tax Identification Number	41-1356149
Entity Address, Address Line One	9924 West 74th Street
Entity Address, City or Town	Eden Prairie
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55344
City Area Code	952
Local Phone Number	500-7000
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		13,868,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Current Assets:
Cash and cash equivalents	$ 48,159	$ 30,785
Available-for-sale securities	17,792	30,313
Accounts receivable, net of allowances of $118 and $130 as of March 31, 2021 and September 30, 2020, respectively	9,096	7,675
Contract assets — royalties and license fees	6,622	6,108
Inventories, net	6,309	5,966
Income tax receivable	1,657	2,391
Prepaids and other	3,406	3,370
Total Current Assets	93,041	86,608
Property and equipment, net	29,745	30,103
Available-for-sale securities	4,071
Deferred income taxes	6,507	7,315
Intangible assets, net	12,028	13,283
Goodwill	27,190	27,185
Other assets	4,513	4,269
Total Assets	177,095	168,763
Current Liabilities:
Accounts payable	1,593	1,515
Accrued liabilities:
Compensation	4,437	6,630
Accrued other	4,162	5,547
Deferred revenue	5,507	5,200
Total Current Liabilities	15,699	18,892
Deferred revenue, less current portion	11,763	10,796
Other long-term liabilities	7,552	8,020
Total Liabilities	35,014	37,708
Commitments and Contingencies (Note 17)
Stockholders’ Equity:
Series A Preferred stock — $.05 par value, 450 shares authorized; no shares issued and outstanding
Common stock — $.05 par value, 45,000 shares authorized; 13,868 and 13,672 shares issued and outstanding as of March 31, 2021 and September 30, 2020, respectively	693	684
Additional paid-in capital	18,516	15,369
Accumulated other comprehensive income	3,231	3,174
Retained earnings	119,641	111,828
Total Stockholders’ Equity	142,081	131,055
Total Liabilities and Stockholders’ Equity	$ 177,095	$ 168,763

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Statement Of Financial Position [Abstract]
Allowances (accounts receivable)	$ 118	$ 130
Series A preferred stock, par value	$ 0.05	$ 0.05
Series A preferred stock, shares authorized	450,000	450,000
Series A preferred stock, shares issued	0	0
Series A preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,868,000	13,672,000
Common stock, shares outstanding	13,868,000	13,672,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenue:
Total revenue	$ 34,995	$ 22,822	$ 57,292	$ 45,438
Operating costs and expenses:
Type of Cost, Good or Service [Extensible List]	Product Sales [Member]	Product Sales [Member]	Product Sales [Member]	Product Sales [Member]
Product costs	$ 4,170	$ 3,769	$ 7,913	$ 6,972
Research and development	12,875	11,935	23,757	24,077
Selling, general and administrative	7,907	6,733	14,930	13,676
Acquired intangible asset amortization	560	541	1,116	1,135
Total operating costs and expenses	25,512	22,978	47,716	45,860
Operating income (loss)	9,483	(156)	9,576	(422)
Other income (expense):
Investment income, net	28	210	69	460
Interest expense	(59)	(30)	(119)	(70)
Foreign exchange gain (loss)	73	(30)	(107)	(77)
Impairment loss on strategic investment and other		(479)		(478)
Other income (expense)	42	(329)	(157)	(165)
Income (loss) before income taxes	9,525	(485)	9,419	(587)
Income tax (provision) benefit	(1,438)	1,947	(1,606)	2,197
Net income	$ 8,087	$ 1,462	$ 7,813	$ 1,610
Basic net income per share	$ 0.59	$ 0.11	$ 0.57	$ 0.12
Diluted net income per share	$ 0.58	$ 0.11	$ 0.56	$ 0.12
Weighted average number of shares outstanding:
Basic	13,746	13,507	13,699	13,474
Diluted	13,981	13,751	13,915	13,779
Product Sales [Member]
Revenue:
Total revenue	$ 11,783	$ 11,770	$ 21,885	$ 21,744
Royalties and License Fees [Member]
Revenue:
Total revenue	20,052	8,221	29,386	18,369
Research, Development and Other [Member]
Revenue:
Total revenue	$ 3,160	$ 2,831	$ 6,021	$ 5,325

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 8,087	$ 1,462	$ 7,813	$ 1,610
Other comprehensive (loss) income:
Net changes related to available-for-sale securities, net of tax	(7)	(174)	(7)	(179)
Foreign currency translation adjustments	(1,768)	(768)	64	273
Other comprehensive (loss) income	(1,775)	(942)	57	94
Comprehensive income	$ 6,312	$ 520	$ 7,870	$ 1,704

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]
Beginning balance at Sep. 30, 2019	$ 122,516	$ 675	$ 10,740	$ 396	$ 110,705
Beginning balance, shares at Sep. 30, 2019	13,504
Net income	$ 1,610				1,610
Other comprehensive income (loss), net of tax	94			94
Issuance of common stock	$ 218	7	211
Issuance of common stock, shares	130
Common stock options exercised, net	$ 100		100
Common stock options exercised, net, shares	20
Purchase of common stock to pay employee taxes	$ (2,269)	(2)	(2,267)
Purchase of common stock to pay employee taxes, shares	(45)
Stock-based compensation	$ 2,697		2,697
Ending balance at Mar. 31, 2020	$ 124,966	680	11,481	490	112,315
Ending balance, shares at Mar. 31, 2020	13,609
Beginning balance at Dec. 31, 2019	$ 123,326	680	10,361	1,432	110,853
Beginning balance, shares at Dec. 31, 2019	13,593
Net income	$ 1,462				1,462
Other comprehensive income (loss), net of tax	(942)			(942)
Issuance of common stock	$ 218		218
Issuance of common stock, shares	5
Common stock options exercised, net	$ 9		9
Common stock options exercised, net, shares	12
Purchase of common stock to pay employee taxes	$ (411)		(411)
Purchase of common stock to pay employee taxes, shares	(1)
Stock-based compensation	$ 1,304		1,304
Ending balance at Mar. 31, 2020	$ 124,966	680	11,481	490	112,315
Ending balance, shares at Mar. 31, 2020	13,609
Beginning balance at Sep. 30, 2020	$ 131,055	684	15,369	3,174	111,828
Beginning balance, shares at Sep. 30, 2020	13,672
Net income	$ 7,813				7,813
Other comprehensive income (loss), net of tax	57			57
Issuance of common stock	$ 296	4	292
Issuance of common stock, shares	89
Common stock options exercised, net	$ 2,240	6	2,234
Common stock options exercised, net, shares	125
Purchase of common stock to pay employee taxes	$ (2,242)	(1)	(2,241)
Purchase of common stock to pay employee taxes, shares	(18)
Stock-based compensation	$ 2,862		2,862
Ending balance at Mar. 31, 2021	$ 142,081	693	18,516	3,231	119,641
Ending balance, shares at Mar. 31, 2021	13,868
Beginning balance at Dec. 31, 2020	$ 133,407	687	16,160	5,006	111,554
Beginning balance, shares at Dec. 31, 2020	13,739
Net income	$ 8,087				8,087
Other comprehensive income (loss), net of tax	(1,775)			(1,775)
Issuance of common stock	$ 296		296
Issuance of common stock, shares	8
Common stock options exercised, net	$ 2,234	6	2,228
Common stock options exercised, net, shares	122
Purchase of common stock to pay employee taxes	$ (1,597)		(1,597)
Purchase of common stock to pay employee taxes, shares	(1)
Stock-based compensation	$ 1,429		1,429
Ending balance at Mar. 31, 2021	$ 142,081	$ 693	$ 18,516	$ 3,231	$ 119,641
Ending balance, shares at Mar. 31, 2021	13,868

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities:
Net income	$ 7,813	$ 1,610
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	3,766	3,600
Stock-based compensation	2,862	2,697
Payment of contingent consideration obligations in excess of acquisition-date value		(608)
Deferred taxes	808	1,388
Loss on strategic investment		479
Provision for credit losses	(12)	137
Other	170	108
Change in operating assets and liabilities:
Accounts receivable and contract asset	(1,908)	1,914
Inventories	(349)	(1,233)
Prepaids and other	(409)	(622)
Accounts payable	(303)	(128)
Accrued liabilities	(2,705)	(1,826)
Income taxes	739	(3,615)
Deferred revenue	1,273	(2,644)
Net cash provided by operating activities	11,745	1,257
Investing Activities:
Purchases of property and equipment	(1,973)	(2,311)
Payment for acquisition of intangible assets	(1,000)
Purchases of available-for-sale securities	(22,875)	(35,863)
Maturities of available-for-sale securities	31,318	27,425
Net cash provided by (used in) investing activities	5,470	(10,749)
Financing Activities:
Issuance of common stock	2,536	318
Payments for taxes related to net share settlement of equity awards	(2,243)	(2,373)
Payment of contingent consideration obligations		(2,592)
Payments for acquisition of in-process research and development	(150)	(1,000)
Net cash provided by (used in) financing activities	143	(5,647)
Effect of exchange rate changes on cash	16	(14)
Net change in cash and cash equivalents	17,374	(15,153)
Cash and Cash Equivalents:
Beginning of period	30,785	30,361
End of period	48,159	15,208
Supplemental Information:
Cash paid for income taxes	16	6
Noncash investing and financing activities:
Acquisition of property and equipment, net of refundable credits in other current assets and liabilities	641	87
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 44	$ 597

Basis of Presentation

Basis of Presentation	6 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Overview Surmodics, Inc. and subsidiaries (“Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics is pursuing development and commercialization of highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development, and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2020, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three and six months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the entire 2021 fiscal year. Risk and Uncertainties The COVID-19 pandemic is having, and may continue to have, an adverse effect on our business, results of operations, financial condition, and cash flows, and its future impacts remain highly uncertain and unpredictable. The Company has considered the disruptions caused by COVID-19, including lower than forecasted sales and customer demand and macroeconomic factors, that may impact its estimates. The Company has assessed the potential impact of the pandemic on certain accounting matters including, but not limited to, estimated sales-based royalties revenue; allowance for credit losses; inventory reserves; and the valuation of goodwill, intangible assets, other long-lived assets and investments, as of March 31, 2021 and through the date of this Quarterly Report on Form 10-Q. As of the date of issuance of these unaudited condensed consolidated financial statements, the extent to which the COVID-19 pandemic may materially impact the Company's financial condition, liquidity or results of operations is uncertain. For further information, refer to “Risk Factors” in Part II, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020. New Accounting Pronouncements Recently Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements In December 2019, the FAS B issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the approach for intraperiod tax allocation and to the methodology for calculating taxes during the quarters, as well as clarifies the accounting for enacted changes in tax laws . We adopted this guidance using a prospective approach in the first quarter of fiscal 2021. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Revenue

Revenue	6 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue	2. Revenue The following table presents the Company’s revenues disaggregated by product classification and by reportable segment. Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Medical Device Product sales $ 5,410 $ 5,455 $ 9,971 $ 10,477 Royalties 7,474 6,714 15,383 15,613 Research, development and other 2,445 2,628 4,746 4,862 License fees 12,578 1,507 14,003 2,756 Total Revenue — Medical Device 27,907 16,304 44,103 33,708 In Vitro Diagnostics Product sales 6,373 6,315 11,914 11,267 Research, development and other 715 203 1,275 463 Total Revenue — In Vitro Diagnostics 7,088 6,518 13,189 11,730 Total Revenue $ 34,995 $ 22,822 $ 57,292 $ 45,438 Contract assets totaled $6.6 million and $6.1 million as of March 31, 2021 and September 30, 2020, respectively. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 3 Collaborative Arrangements.

Collaborative Arrangement

Collaborative Arrangement	6 Months Ended
	Mar. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangement	3. Collaborative Arrangement On February 26, 2018, the Company entered into an agreement with Abbott Vascular, Inc. (“Abbott”) whereby Abbott has exclusive worldwide commercialization rights for Surmodics' SurVeil TM SurVeil TM SurVeil SurVeil SurVeil As of March 31, 2021, the Company has received payments totaling $60.8 million under the Abbott Agreement, which consist of the following: $25 million upfront fee in fiscal 2018, $10 million milestone payment in fiscal 2019, $10.8 million milestone payment in the third quarter of fiscal 2020, and $15 million milestone payment in the second quarter of fiscal 2021 upon receipt by Abbott of the clinical study report and related materials from the TRANSCEND pivotal trial that demonstrated the primary safety and primary clinical endpoints are non-inferior to the control device. As of March 31, 2021, the Company may receive an additional contingent milestone payment of up to $30 million, pursuant to the terms of the Abbott Agreement, upon premarket approval (“PMA”) of our SurVeil Revenue recognized from the Abbott agreement totaled $12.5 million and $1.5 million for the three months ended March 31, 2021 and 2020, respectively, and $13.8 million and $2.8 million for the six months ended March 31, 2021 and 2020, respectively. The amount of revenue recognized from the Abbott Agreement that was included in the respective beginning of fiscal year balances of deferred revenue on the condensed consolidated balance sheets totaled $3.0 million and $2.8 million for the six months ended March 31, 2021 and 2020, respectively. As of March 31, 2021 and September 30, 2020, deferred revenue from the upfront and milestone payments received under the Abbott Agreement of $17.1 million and $15.9 million, respectively, was recorded in the condensed consolidated balance sheets. As of March 31, 2021, the estimated revenue expected to be recognized in future periods related to performance obligations that are unsatisfied for executed contracts with an original duration of one year or more totaled $17.1 million. These remaining performance obligations relate to the Abbott Agreement, exclude the potential contingent milestone payment under the Abbott Agreement, and are expected to be recognized over the next five years through fiscal 2025 as services, principally the TRANSCEND clinical trial, are completed.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. In valuing Level 3 assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. Assets measured at fair value on a recurring basis by level of the fair value hierarchy were as follows: March 31, 2021 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents $ — $ 31,135 $ — $ 31,135 Available-for-sale securities — 21,863 — 21,863 Total assets $ — $ 52,998 $ — $ 52,998 September 30, 2020 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents $ — $ 18,634 $ — $ 18,634 Available-for-sale securities — 30,313 — $ 30,313 Total assets $ — $ 48,947 $ — $ 48,947 There were no transfers of assets between amounts measured using Level 3 fair value measurements during the six months ended March 31, 2021 and 2020.

Investments

Investments	6 Months Ended
	Mar. 31, 2021
Investments Debt And Equity Securities [Abstract]
Investments	5. Investments The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: March 31, 2021 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 21,870 $ 1 $ (8 ) $ 21,863 $ 17,792 $ 4,071 Total $ 21,870 $ 1 $ (8 ) $ 21,863 $ 17,792 $ 4,071 September 30, 2020 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — Total $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ —

Inventories

Inventories	6 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories consisted of the following components: March 31, September 30, (In thousands) 2021 2020 Raw materials $ 3,758 $ 3,758 Work-in process 1,151 817 Finished products 1,400 1,391 Total $ 6,309 $ 5,966

Other Assets

Other Assets	6 Months Ended
	Mar. 31, 2021
Investments All Other Investments [Abstract]
Other Assets	7. Other Assets Other assets consisted of the following: March 31, September 30, (In thousands) 2021 2020 Operating lease right-of-use assets 2,406 2,508 Other noncurrent assets 2,107 1,761 Other assets $ 4,513 $ 4,269 Other noncurrent assets include prepaid expenses related to our ongoing clinical trials and a receivable related to refundable Irish research and development tax credits.

Intangible Assets

Intangible Assets	6 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets Intangible assets consisted of the following: March 31, 2021 (In thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,359 $ (8,283 ) $ 5,076 Developed technology 11.5 9,686 (4,659 ) 5,027 Patents and other 14.1 3,551 (2,206 ) 1,345 Total definite-lived intangible assets 26,596 (15,148 ) 11,448 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,176 $ (15,148 ) $ 12,028 September 30, 2020 (In thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,356 $ (7,594 ) $ 5,762 Developed technology 11.5 9,685 (4,200 ) 5,485 Patents and other 14.1 3,551 (2,095 ) 1,456 Total definite-lived intangible assets 26,592 (13,889 ) 12,703 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,172 $ (13,889 ) $ 13,283 Intangible asset amortization expense was $0.6 million for both the three months ended March 31, 2021 and 2020 and $1.3 million for both the six months ended March 31, 2021 and 2020. Based on the intangible assets in service as of March 31, 2021, estimated amortization expense for the remainder of fiscal 2021 and each of the next five fiscal years is as follows: (In thousands) Remainder of 2021 $ 1,232 2022 2,449 2023 1,844 2024 1,751 2025 1,712 2026 754 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

Goodwill

Goodwill	6 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	9. Goodwill Changes in the carrying amount of goodwill by segment were as follows: (In thousands) In Vitro Diagnostics Medical Device Total Goodwill as of September 30, 2020 $ 8,010 $ 19,175 $ 27,185 Currency translation adjustment — 5 5 Goodwill as of March 31, 2021 $ 8,010 $ 19,180 $ 27,190

Accrued Other Liabilities

Accrued Other Liabilities	6 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Accrued Other Liabilities	10. Accrued Other Liabilities Accrued other liabilities consisted of the following: March 31, September 30, (In thousands) 2021 2020 Accrued professional fees $ 403 $ 239 Accrued clinical study expense 1,708 2,206 Accrued purchases 810 647 Acquisition of in-process research and development and intangible assets 482 1,148 Due to customers 7 321 Construction-in-progress — 272 Operating lease liability, current portion 464 436 Other 288 278 Total accrued other liabilities $ 4,162 $ 5,547

Debt

Debt	6 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Debt	11. Debt On September 14, 2020, the Company entered into a secured revolving credit facility pursuant to a Loan and Security Agreement (the "Loan Agreement") with Bridgewater Bank (the “Bank”). The Loan Agreement provides for availability under a secured revolving line of credit of up to $25 million (the "Loan"). The outstanding balance on the Loan was zero as of March 31, 2021 and September 30, 2020. Availability under the Loan is subject to a borrowing base that equals 80% of the margin value of securities collateral that has been pledged to the Bank. The Loan will initially mature on September 14, 2021, but the maturity date may be extended by the Company for up to two extension periods of twelve months subject to certain conditions set forth in the Loan Agreement. The Company's obligations under the Loan Agreement are secured by substantially all of the Company’s and its material subsidiaries' assets, other than intellectual property, real estate and foreign assets, including equity in foreign subsidiaries. The Company has also pledged the stock of certain of its subsidiaries to secure such obligations. Interest under the Loan Agreement accrues at a rate per annum equal to the greater of (i) 3.25% per annum and (ii) the 90-day interest rate yield for U.S. Government Treasury Securities plus 2.75% per annum. A facility fee is payable on unused commitments at a rate of 0.075% quarterly. For the six months ended March 31, 2021, unused commitment fees, reported within interest expense on the condensed consolidated statements of operations, totaled less than $0.1 million. The Loan Agreement contains affirmative and negative covenants customary for a transaction of this type which, among other things, require the Company to meet certain financial tests, including (i) minimum liquidity, (ii) minimum current ratio, (iii) minimum adjusted EBITDA, and (iv) minimum tangible net worth. The Loan Agreement also contains covenants which, among other things, limit the Company's ability to incur additional debt, make certain investments, create or permit certain liens, create or permit restrictions on the ability of subsidiaries to pay dividends or make other distributions, consolidate or merge and engage in other activities customarily restricted in such agreements, in each case subject to exceptions permitted by the Loan Agreement. The Loan Agreement also contains customary events of default, the occurrence of which would permit the Bank to terminate its commitment and accelerate the Loan.

Stock-based Compensation Plans

Stock-based Compensation Plans	6 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation Plans	12. Stock-based Compensation Plans The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Product costs $ 32 $ 15 $ 69 $ 48 Research and development 305 168 589 430 Selling, general and administrative 1,092 1,121 2,204 2,219 Total $ 1,429 $ 1,304 $ 2,862 $ 2,697 As of March 31, 2021, approximately $10.1 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years. Stock Option Awards During the six months ended March 31, 2021 and 2020, the Company awarded 234,000 and 261,000 options to officers, directors and key employees with a weighted average grant date fair value per option of $13.86 and $14.24, respectively. Restricted Stock Awards During the six months ended March 31, 2021 and 2020, the Company awarded 65,000 and 60,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of $37.48 and $41.88, respectively. Restricted Stock Unit Awards During the six months ended March 31, 2021 and 2020, the Company awarded 12,000 and 17,000 restricted stock units, respectively, to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of $45.13 and $40.73, respectively. Employee Stock Purchase Plan Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan (“ESPP”) approved by our shareholders. Shares issued under the ESPP totaled 8,000 and 7,000 for the six months ended March 31, 2021 and 2020, respectively.

Net Income Per Share Data

Net Income Per Share Data	6 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income Per Share Data	13. Net Income Per Share Data Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units. The following table sets forth the calculation of diluted weighted average shares outstanding: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Basic weighted average shares outstanding 13,746 13,507 13,699 13,474 Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units 235 244 216 305 Diluted weighted average shares outstanding 13,981 13,751 13,915 13,779 The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase less than 0.1 million shares of common stock for both the three months ended March 31, 2021 and 2020 and 0.1 million and less than 0.1 million shares of common stock for the six months ended March 31, 2021 and 2020, respectively, as their inclusion would have had an antidilutive effect on diluted net income per share for the period.

Income Taxes

Income Taxes	6 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes For interim income tax reporting, the Company estimates its annual effective tax rate and applies it to fiscal year-to-date pretax income (loss), excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company recorded income tax expense of $(1.4) million and income tax benefit of $1.9 million for the three months ended March 31, 2021 and 2020, respectively, and income tax expense of $(1.6) million and income tax benefit of $2.2 million for the six months ended March 31, 2021 and 2020, respectively. For the three and six months ended March 31, 2020, the income tax benefit includes a discrete tax benefit of $1.8 million as a result of our ability under the Coronavirus Aid, Relieve and Economic Security Act (the “CARES Act”), enacted in March 2020, to carry back net operating losses (“NOLs”) incurred to periods when the statutory rate was 35% versus the current tax rate of 21%. The effective income tax rate for the three and six months ended March 31, 2021 and 2020 differs from the U.S. federal statutory tax rate of 21% primarily due to the discrete tax benefits recognized under the CARES Act in the second quarter of fiscal 2020, favorable impacts of the U.S. federal research and development tax credits, stock award activity, and operating results of our Irish subsidiary, where tax benefit is offset by a valuation allowance. The Company recognized discrete tax benefits related to stock-based compensation awards vested, expired, cancelled and exercised of $0.7 million and less than $0.1 million in the three months ended March 31, 2021 and 2020, respectively and $0.7 million and $0.3 million in the six months ended March 31, 2021 and 2020, respectively. The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate was $3.1 million and $2.7 million as of March 31, 2021 and September 30, 2020, respectively. Interest and penalties related to unrecognized tax benefits are recorded in the income tax benefit. The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. income tax returns for years prior to fiscal 2017 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2009. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2014. Additionally, the Company has been indemnified of liability for any taxes relating to Creagh Medical and NorMedix for periods prior to their respective acquisition dates, pursuant to the terms of the related share purchase agreements. There were no undistributed earnings in foreign subsidiaries as of March 31, 2021 and September 30, 2020.

Segment Information

Segment Information	6 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Information	15. Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We operate two reportable segments: • Medical Device: Surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular, and structural heart, among others; and the design, development, and manufacture of interventional medical devices, primarily balloons and catheters, including drug-coated balloons, for peripheral arterial disease treatment and other applications; and • In Vitro Diagnostics (“IVD”): Design, development and manufacture of component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens. Segment revenue, operating income (loss), and depreciation and amortization were as follows: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Revenue: Medical Device $ 27,907 $ 16,304 $ 44,103 $ 33,708 In Vitro Diagnostics 7,088 6,518 13,189 11,730 Total revenue $ 34,995 $ 22,822 $ 57,292 $ 45,438 Operating income (loss): Medical Device $ 8,564 $ (1,453 ) $ 7,971 $ (1,876 ) In Vitro Diagnostics 3,809 3,462 7,029 6,061 Total segment operating income 12,373 2,009 15,000 4,185 Corporate (2,890 ) (2,165 ) (5,424 ) (4,607 ) Total operating income (loss) $ 9,483 $ (156 ) $ 9,576 $ (422 ) Depreciation and amortization: Medical Device $ 1,721 $ 1,439 $ 3,373 $ 2,894 In Vitro Diagnostics 88 109 193 219 Corporate 97 248 200 487 Total depreciation and amortization $ 1,906 $ 1,796 $ 3,766 $ 3,600 The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments. Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Leases

Leases	6 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Leases	16. Leases Operating lease right-of-use assets and lease liabilities were as follows: March 31, September 30, (In thousands) 2021 2020 Right-of-use assets: Other assets $ 2,406 $ 2,508 Operating lease liabilities: Other accrued liabilities $ 464 $ 436 Other long-term liabilities 3,293 3,340 Total operating lease liabilities $ 3,757 $ 3,776 As of March 31, 2021, operating lease maturities for the remainder of fiscal 2021 and each of the next five fiscal years were as follows: (In thousands) Remainder of 2021 $ 303 2022 612 2023 625 2024 638 2025 651 2026 595 Thereafter 894 Total expected operating lease payments 4,318 Less: Imputed interest (561 ) Total operating lease liabilities $ 3,757 Operating lease cost was $0.2 million and $0.1 million for the three months ended March 31, 2021 and 2020, respectively, and $0.4 million and $0.3 million for the six months ended March 31, 2021 and 2020, respectively. Cash paid for operating lease liabilities approximated operating lease cost for the three and six month periods ended March 31, 2021 and 2020.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Mar. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	17. Commitments and Contingencies InnoCore Technologies BV . In 2006, the Company entered into a license agreement whereby the Company obtained an exclusive license to a drug-delivery coating for licensed products within the vascular field, which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual, minimum payment of approximately $0.2 million (at the Euro to US dollar exchange rate as of March 31, 2021) until the last patent expires, which is currently estimated to be May 2027. The total minimum future payments associated with this license are approximately $1.5 million as of March 31, 2021. The license is currently utilized by one of the Company’s drug delivery customers. Clinical Trials. The Company has engaged clinical trial clinical research organization (“CRO”) consultants to assist with the administration of its ongoing clinical trials. The Company has executed separate contracts with two CROs for services rendered in connection with the TRANSCEND pivotal clinical trial for the DCB, including pass-through expenses paid by the CROs, of up to approximately $29 million in the aggregate. As of March 31, 2021, an estimated $8 million remains to be paid on these contracts, which may vary depending on actual pass-through expenses incurred to execute the trial. The Company estimates that the total cost of the TRANSCEND clinical trial will be in the range of $35 million to $40 million from inception to completion. In the event the Company were to terminate any trial, it may incur certain financial penalties which would become payable to the CRO for costs to wind down the terminated trial Asset Acquisitions. In the fiscal 2019, the Company acquired certain intellectual property assets supporting ongoing development of the Company’s medical device pipeline and paid the sellers $0.8 million in fiscal 2019 and $0.2 million in the first quarter of fiscal 2021. An additional $1.1 million in payments is contingent upon achievement of certain strategic milestones within a contingency period ending in 2022. In fiscal 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the “Embolitech Transaction”). As part of the Embolitech Transaction, the Company paid the sellers $5.0 million in fiscal 2018, $1.0 million in the second quarter of fiscal 2020, and $1.0 million in the first quarter of fiscal 2021. The Company is obligated to pay additional installments totaling $2.5 million in fiscal 2022 through fiscal 2024. These payments may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional $1.0 million payment is contingent upon the achievement of certain regulatory milestones within a contingency period ending in 2033. As of March 31, 2021, $0.5 million and $1.8 million related to these asset acquisitions was recorded in other accrued liabilities and other long-term liabilities, respectively, on the condensed consolidated balance sheets.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, Measurement of Credit Losses on Financial Statements In December 2019, the FAS B issued ASU 2019-12, Simplifying the Accounting for Income Taxes , which eliminates certain exceptions related to the approach for intraperiod tax allocation and to the methodology for calculating taxes during the quarters, as well as clarifies the accounting for enacted changes in tax laws . We adopted this guidance using a prospective approach in the first quarter of fiscal 2021. The adoption of this guidance did not have a material impact on the Company’s condensed consolidated financial statements. No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s condensed consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Mar. 31, 2021
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Product Classification and Reportable Segment	The following table presents the Company’s revenues disaggregated by product classification and by reportable segment. Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Medical Device Product sales $ 5,410 $ 5,455 $ 9,971 $ 10,477 Royalties 7,474 6,714 15,383 15,613 Research, development and other 2,445 2,628 4,746 4,862 License fees 12,578 1,507 14,003 2,756 Total Revenue — Medical Device 27,907 16,304 44,103 33,708 In Vitro Diagnostics Product sales 6,373 6,315 11,914 11,267 Research, development and other 715 203 1,275 463 Total Revenue — In Vitro Diagnostics 7,088 6,518 13,189 11,730 Total Revenue $ 34,995 $ 22,822 $ 57,292 $ 45,438

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Assets Measured at Fair Value on Recurring Basis	Assets measured at fair value on a recurring basis by level of the fair value hierarchy were as follows: March 31, 2021 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents $ — $ 31,135 $ — $ 31,135 Available-for-sale securities — 21,863 — 21,863 Total assets $ — $ 52,998 $ — $ 52,998 September 30, 2020 (In thousands) Quoted Prices in Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value Assets Cash equivalents $ — $ 18,634 $ — $ 18,634 Available-for-sale securities — 30,313 — $ 30,313 Total assets $ — $ 48,947 $ — $ 48,947

Investments (Tables)

Investments (Tables)	6 Months Ended
	Mar. 31, 2021
Investments Debt And Equity Securities [Abstract]
Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities	The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows: March 31, 2021 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 21,870 $ 1 $ (8 ) $ 21,863 $ 17,792 $ 4,071 Total $ 21,870 $ 1 $ (8 ) $ 21,863 $ 17,792 $ 4,071 September 30, 2020 Valuation Balance Sheet Classification (In thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Current Assets Noncurrent Assets Commercial paper and corporate bonds $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ — Total $ 30,313 $ 19 $ (19 ) $ 30,313 $ 30,313 $ —

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following components: March 31, September 30, (In thousands) 2021 2020 Raw materials $ 3,758 $ 3,758 Work-in process 1,151 817 Finished products 1,400 1,391 Total $ 6,309 $ 5,966

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Mar. 31, 2021
Investments All Other Investments [Abstract]
Summary of Other Assets	Other assets consisted of the following: March 31, September 30, (In thousands) 2021 2020 Operating lease right-of-use assets 2,406 2,508 Other noncurrent assets 2,107 1,761 Other assets $ 4,513 $ 4,269

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: March 31, 2021 (In thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,359 $ (8,283 ) $ 5,076 Developed technology 11.5 9,686 (4,659 ) 5,027 Patents and other 14.1 3,551 (2,206 ) 1,345 Total definite-lived intangible assets 26,596 (15,148 ) 11,448 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,176 $ (15,148 ) $ 12,028 September 30, 2020 (In thousands) Weighted Average Original Life (Years) Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 8.9 $ 13,356 $ (7,594 ) $ 5,762 Developed technology 11.5 9,685 (4,200 ) 5,485 Patents and other 14.1 3,551 (2,095 ) 1,456 Total definite-lived intangible assets 26,592 (13,889 ) 12,703 Unamortized intangible assets: Trademarks and trade names 580 — 580 Total intangible assets $ 27,172 $ (13,889 ) $ 13,283
Estimated Amortization Expense	Based on the intangible assets in service as of March 31, 2021, estimated amortization expense for the remainder of fiscal 2021 and each of the next five fiscal years is as follows: (In thousands) Remainder of 2021 $ 1,232 2022 2,449 2023 1,844 2024 1,751 2025 1,712 2026 754

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Mar. 31, 2021
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Carrying Amount of Goodwill By Segment	Changes in the carrying amount of goodwill by segment were as follows: (In thousands) In Vitro Diagnostics Medical Device Total Goodwill as of September 30, 2020 $ 8,010 $ 19,175 $ 27,185 Currency translation adjustment — 5 5 Goodwill as of March 31, 2021 $ 8,010 $ 19,180 $ 27,190

Accrued Other Liabilities (Tabl

Accrued Other Liabilities (Tables)	6 Months Ended
	Mar. 31, 2021
Payables And Accruals [Abstract]
Schedule of Accrued Other Liabilities	Accrued other liabilities consisted of the following: March 31, September 30, (In thousands) 2021 2020 Accrued professional fees $ 403 $ 239 Accrued clinical study expense 1,708 2,206 Accrued purchases 810 647 Acquisition of in-process research and development and intangible assets 482 1,148 Due to customers 7 321 Construction-in-progress — 272 Operating lease liability, current portion 464 436 Other 288 278 Total accrued other liabilities $ 4,162 $ 5,547

Stock-based Compensation Plans

Stock-based Compensation Plans (Tables)	6 Months Ended
	Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation Expenses	Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Product costs $ 32 $ 15 $ 69 $ 48 Research and development 305 168 589 430 Selling, general and administrative 1,092 1,121 2,204 2,219 Total $ 1,429 $ 1,304 $ 2,862 $ 2,697

Net Income Per Share Data (Tabl

Net Income Per Share Data (Tables)	6 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Calculation of Diluted Weighted Average Shares Outstanding	The following table sets forth the calculation of diluted weighted average shares outstanding: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Basic weighted average shares outstanding 13,746 13,507 13,699 13,474 Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units 235 244 216 305 Diluted weighted average shares outstanding 13,981 13,751 13,915 13,779

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Revenue, Operating Income (Loss) and Depreciation and Amortization	Segment revenue, operating income (loss), and depreciation and amortization were as follows: Three Months Ended Six Months Ended March 31, March 31, (In thousands) 2021 2020 2021 2020 Revenue: Medical Device $ 27,907 $ 16,304 $ 44,103 $ 33,708 In Vitro Diagnostics 7,088 6,518 13,189 11,730 Total revenue $ 34,995 $ 22,822 $ 57,292 $ 45,438 Operating income (loss): Medical Device $ 8,564 $ (1,453 ) $ 7,971 $ (1,876 ) In Vitro Diagnostics 3,809 3,462 7,029 6,061 Total segment operating income 12,373 2,009 15,000 4,185 Corporate (2,890 ) (2,165 ) (5,424 ) (4,607 ) Total operating income (loss) $ 9,483 $ (156 ) $ 9,576 $ (422 ) Depreciation and amortization: Medical Device $ 1,721 $ 1,439 $ 3,373 $ 2,894 In Vitro Diagnostics 88 109 193 219 Corporate 97 248 200 487 Total depreciation and amortization $ 1,906 $ 1,796 $ 3,766 $ 3,600

Leases (Tables)

Leases (Tables)	6 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities	Operating lease right-of-use assets and lease liabilities were as follows: March 31, September 30, (In thousands) 2021 2020 Right-of-use assets: Other assets $ 2,406 $ 2,508 Operating lease liabilities: Other accrued liabilities $ 464 $ 436 Other long-term liabilities 3,293 3,340 Total operating lease liabilities $ 3,757 $ 3,776
Schedule of Operating Lease Maturities	As of March 31, 2021, operating lease maturities for the remainder of fiscal 2021 and each of the next five fiscal years were as follows: (In thousands) Remainder of 2021 $ 303 2022 612 2023 625 2024 638 2025 651 2026 595 Thereafter 894 Total expected operating lease payments 4,318 Less: Imputed interest (561 ) Total operating lease liabilities $ 3,757

Revenue - Summary of Revenues D

Revenue - Summary of Revenues Disaggregated by Product Classification and Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Disaggregation Of Revenue [Line Items]
Total revenue	$ 34,995	$ 22,822	$ 57,292	$ 45,438
Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11,783	11,770	21,885	21,744
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	20,052	8,221	29,386	18,369
Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	3,160	2,831	6,021	5,325
Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	34,995	22,822	57,292	45,438
Operating Segments [Member] | Medical Device [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	27,907	16,304	44,103	33,708
Operating Segments [Member] | Medical Device [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,410	5,455	9,971	10,477
Operating Segments [Member] | Medical Device [Member] | Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	7,474	6,714	15,383	15,613
Operating Segments [Member] | Medical Device [Member] | Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,445	2,628	4,746	4,862
Operating Segments [Member] | Medical Device [Member] | License Fees [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	12,578	1,507	14,003	2,756
Operating Segments [Member] | In Vitro Diagnostics [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	7,088	6,518	13,189	11,730
Operating Segments [Member] | In Vitro Diagnostics [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	6,373	6,315	11,914	11,267
Operating Segments [Member] | In Vitro Diagnostics [Member] | Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 715	$ 203	$ 1,275	$ 463

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Revenue From Contract With Customer [Abstract]
Contract assets — royalties and license fees	$ 6,622	$ 6,108

Collaborative Arrangement - Add

Collaborative Arrangement - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue	$ 34,995,000		$ 22,822,000	$ 57,292,000	$ 45,438,000
Abbott Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received				60,800,000
Total revenue	12,500,000		$ 1,500,000	13,800,000	2,800,000
Collaboration revenue recognized included in balance at beginning of period				3,000,000	$ 2,800,000
Upfront and milestone fee payment included in deferred revenue	17,100,000			17,100,000				$ 15,900,000
Abbott Agreement [Member] | Upfront Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received							$ 25,000,000
Abbott Agreement [Member] | Milestone Payment [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement payment received	15,000,000	$ 10,800,000				$ 10,000,000
Abbott Agreement [Member] | Maximum [Member] | PMA Milestone [Member] | TRANSCEND Clinical Trial [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement additional potential milestone payments receivable	$ 30,000,000			$ 30,000,000

Collaborative Arrangement - A_2

Collaborative Arrangement - Additional Information (Detail 1) - Abbott Agreement [Member] - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-04-01 $ in Millions	Mar. 31, 2021USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining performance obligation, amount	$ 17.1
Remaining performance obligation, satisfaction period	5 years

Fair Value Measurements - Asset

Fair Value Measurements - Assets Measured at Fair Value on Recurring Basis (Detail) - Assets Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 52,998	$ 48,947
Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	21,863	30,313
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	31,135	18,634
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	52,998	48,947
Significant Other Observable Inputs (Level 2) [Member] | Available-for-sale securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	21,863	30,313
Significant Other Observable Inputs (Level 2) [Member] | Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 31,135	$ 18,634

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Transfers in or out Level 3, Assets	$ 0	$ 0

Investments - Amortized Cost, U

Investments - Amortized Cost, Unrealized Holding Gains and (Losses) and Fair Value of Available-for-sale Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 21,870	$ 30,313
Unrealized Gains	1	19
Unrealized Losses	(8)	(19)
Fair Value	21,863	30,313
Current Assets	17,792	30,313
Noncurrent Assets	4,071
Commercial paper and corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	21,870	30,313
Unrealized Gains	1	19
Unrealized Losses	(8)	(19)
Fair Value	21,863	30,313
Current Assets	17,792	$ 30,313
Noncurrent Assets	$ 4,071

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 3,758	$ 3,758
Work-in process	1,151	817
Finished products	1,400	1,391
Total	$ 6,309	$ 5,966

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Schedule of Investments [Line Items]
Other assets	$ 4,513	$ 4,269
Operating Lease Right-of-Use Assets [Member]
Schedule of Investments [Line Items]
Other assets	2,406	2,508
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets	$ 2,107	$ 1,761

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Mar. 31, 2021	Sep. 30, 2020
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (15,148)	$ (13,889)
Intangible assets, Gross Carrying Amount	27,176	27,172
Intangible assets, Net	$ 12,028	$ 13,283
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years 10 months 24 days	8 years 10 months 24 days
Definite-lived intangible assets, Gross Carrying Amount	$ 13,359	$ 13,356
Definite-lived intangible assets, Accumulated Amortization	(8,283)	(7,594)
Definite-lived intangible assets, Net	$ 5,076	$ 5,762
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 6 months	11 years 6 months
Definite-lived intangible assets, Gross Carrying Amount	$ 9,686	$ 9,685
Definite-lived intangible assets, Accumulated Amortization	(4,659)	(4,200)
Definite-lived intangible assets, Net	$ 5,027	$ 5,485
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	14 years 1 month 6 days	14 years 1 month 6 days
Definite-lived intangible assets, Gross Carrying Amount	$ 3,551	$ 3,551
Definite-lived intangible assets, Accumulated Amortization	(2,206)	(2,095)
Definite-lived intangible assets, Net	1,345	1,456
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	26,596	26,592
Definite-lived intangible assets, Accumulated Amortization	(15,148)	(13,889)
Definite-lived intangible assets, Net	11,448	12,703
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Amortization expense	$ 0.6	$ 0.6	$ 1.3	$ 1.3

Intangible Assets - Estimated A

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Mar. 31, 2021USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 1,232
2022	2,449
2023	1,844
2024	1,751
2025	1,712
2026	$ 754

Goodwill - Schedule of Carrying

Goodwill - Schedule of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	6 Months Ended
	Mar. 31, 2021USD ($)
Goodwill [Line Items]
Goodwill as of September 30, 2020	$ 27,185
Currency translation adjustment	5
Goodwill as of March 31, 2021	27,190
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2020	8,010
Goodwill as of March 31, 2021	8,010
Medical Device [Member]
Goodwill [Line Items]
Goodwill as of September 30, 2020	19,175
Currency translation adjustment	5
Goodwill as of March 31, 2021	$ 19,180

Accrued Other Liabilities - Sch

Accrued Other Liabilities - Schedule of Accrued Other Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 403	$ 239
Accrued clinical study expense	1,708	2,206
Accrued purchases	810	647
Acquisition of in-process research and development and intangible assets	482	1,148
Due to customers	7	321
Construction-in-progress		272
Operating lease liability, current portion	464	436
Other	288	278
Total accrued other liabilities	$ 4,162	$ 5,547

Debt - Additional Information (

Debt - Additional Information (Details) - Secured Revolving Credit Facility [Member] - Loan and Security Agreement [Member] - USD ($)	6 Months Ended
	Mar. 31, 2021	Sep. 30, 2020	Sep. 14, 2020
Line Of Credit Facility [Line Items]
Revolving credit facility, maximum borrowing capacity			$ 25,000,000
Revolving credit facility, outstanding balance	$ 0	$ 0
Revolving credit facility, borrowing base	Availability under the Loan is subject to a borrowing base that equals 80% of the margin value of securities collateral that has been pledged to the Bank.
Revolving credit facility, maturity date	Sep. 14, 2021
Debt instrument, maturity date, description	maturity date may be extended by the Company for up to two extension periods of twelve months subject to certain conditions set forth in the Loan Agreement.
Revolving credit facility, interest rate	Interest under the Loan Agreement accrues at a rate per annum equal to the greater of (i) 3.25% per annum and (ii) the 90-day interest rate yield for U.S. Government Treasury Securities plus 2.75% per annum.
Revolving credit facility, basis spread on variable rate	2.75%
Revolving credit facility, unused commitment fee rate	0.075%
Revolving credit facility, frequency of payments	quarterly
Interest Expense [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, unused commitment fee	$ 100,000
Minimum [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility, interest rate	3.25

Stock-based Compensation Plan_2

Stock-based Compensation Plans - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,429	$ 1,304	$ 2,862	$ 2,697
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	32	15	69	48
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	305	168	589	430
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,092	$ 1,121	$ 2,204	$ 2,219

Stock-based Compensation Plan_3

Stock-based Compensation Plans - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs, nonvested awards, amount	$ 10.1
Unrecognized compensation costs, nonvested awards, weighted average recognition period	2 years 6 months
Stock Option Awards [Member]
Stock-Based Compensation Activity [Line Items]
Units granted	234,000	261,000
Weighted average grant date fair value per unit	$ 13.86	$ 14.24
Restricted Stock Awards [Member]
Stock-Based Compensation Activity [Line Items]
Units granted	65,000	60,000
Weighted average grant date fair value	$ 37.48	$ 41.88
Restricted Stock Unit Awards [Member]
Stock-Based Compensation Activity [Line Items]
Units granted	12,000	17,000
Weighted average grant date fair value	$ 45.13	$ 40.73
Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Shares issued	8,000	7,000

Net Income Per Share Data - Cal

Net Income Per Share Data - Calculation of Diluted Weighted Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Basic weighted average shares outstanding	13,746	13,507	13,699	13,474
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units	235	244	216	305
Diluted weighted average shares outstanding	13,981	13,751	13,915	13,779

Net Income Per Share Data - Add

Net Income Per Share Data - Additional Information (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Anti-dilutive outstanding stock options	0.1	0.1	0.1	0.1

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended			6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2017	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income tax (expense) benefit	$ (1,438,000)	$ 1,947,000		$ (1,606,000)	$ 2,197,000
Discrete tax benefit under CARES Act		$ 1,800,000			$ 1,800,000
U.S. federal statutory tax rate	21.00%	21.00%	35.00%	21.00%	21.00%
Discrete tax benefits related to stock-based compensation awards	$ 700,000	$ 100,000		$ 700,000	$ 300,000
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	3,100,000			3,100,000		$ 2,700,000
Undistributed earnings in foreign subsidiaries	$ 0			$ 0		$ 0

Segment Information - Additiona

Segment Information - Additional Information (Detail)	6 Months Ended
	Mar. 31, 2021Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Segment R

Segment Information - Segment Revenue, Operating Income (Loss) and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 34,995	$ 22,822	$ 57,292	$ 45,438
Operating income (loss)	9,483	(156)	9,576	(422)
Depreciation and amortization	1,906	1,796	3,766	3,600
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	34,995	22,822	57,292	45,438
Operating income (loss)	12,373	2,009	15,000	4,185
Operating Segments [Member] | Medical Device [Member]
Segment Reporting Information [Line Items]
Revenue	27,907	16,304	44,103	33,708
Operating income (loss)	8,564	(1,453)	7,971	(1,876)
Depreciation and amortization	1,721	1,439	3,373	2,894
Operating Segments [Member] | In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Revenue	7,088	6,518	13,189	11,730
Operating income (loss)	3,809	3,462	7,029	6,061
Depreciation and amortization	88	109	193	219
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income (loss)	(2,890)	(2,165)	(5,424)	(4,607)
Depreciation and amortization	$ 97	$ 248	$ 200	$ 487

Leases - Balance Sheet Classifi

Leases - Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Right-of-use assets:
Other assets	$ 2,406	$ 2,508
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Operating lease liabilities:
Other accrued liabilities	$ 464	$ 436
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Accrued other	Accrued other
Other long-term liabilities	$ 3,293	$ 3,340
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Total operating lease liabilities	$ 3,757	$ 3,776

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Maturities (Detail) - USD ($) $ in Thousands	Mar. 31, 2021	Sep. 30, 2020
Operating Lease Liabilities Payments Due [Abstract]
Remainder of 2021	$ 303
2022	612
2023	625
2024	638
2025	651
2026	595
Thereafter	894
Total expected operating lease payments	4,318
Less: Imputed interest	(561)
Total operating lease liabilities	$ 3,757	$ 3,776

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating lease cost	$ 0.2	$ 0.1	$ 0.4	$ 0.3

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended	12 Months Ended		36 Months Ended
	Dec. 31, 2020	Mar. 31, 2020	Mar. 31, 2021	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2024	Sep. 30, 2020
Commitments And Contingencies [Line Items]
Payments to acquire intangible assets			$ 1,000,000
Other accrued liabilities current			4,162,000				$ 5,547,000
Other long-term liabilities			7,552,000				8,020,000
Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Payments to acquire in-process research and development		$ 1,000,000			$ 5,000,000
Contingent payments upon achievement of regulatory milestones			$ 1,000,000
Installment payment beginning period			2022
Installment payment ending period			2024
CRO [Member]
Commitments And Contingencies [Line Items]
Contractual obligation remaining to be paid			$ 8,000,000
CRO [Member] | Minimum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation			35,000,000
CRO [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation			40,000,000
CRO [Member] | Maximum [Member] | CRO Pass-through Expenses [Member]
Commitments And Contingencies [Line Items]
Gross contractual obligation			29,000,000
Intellectual Property Assets [Member]
Commitments And Contingencies [Line Items]
Other accrued liabilities current			500,000				1,100,000
Other long-term liabilities			$ 1,800,000				$ 2,200,000
Intellectual Property Assets [Member] | Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingency period ending year			2033
Payments to acquire intangible assets	$ 1,000,000
Intellectual Property Assets [Member] | Embolitech LLC [Member] | Forecast [Member]
Commitments And Contingencies [Line Items]
Contractual obligation payable in fiscal 2022 through fiscal 2024						$ 2,500,000
Intellectual Property Assets [Member] | InnoCore Technologies BV [Member]
Commitments And Contingencies [Line Items]
License agreement commencement year			2006
Annual minimum payments for licenses			$ 200,000
Patent expiry date			2027-05
Future minimum payments associated with license			$ 1,500,000
Intellectual Property Assets [Member] | Medical Device [Member]
Commitments And Contingencies [Line Items]
Payments to acquire in-process research and development	$ 200,000			$ 800,000
Contingent payments upon achievement of regulatory milestones			$ 1,100,000
Contingency period ending year			2022